Cite
Taira N, Kashiwabara K, Tsurutani J, et al. Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. Breast Cancer. 2022;29(1):186-188doi: 10.1007/s12282-021-01296-z.
Taira, N., Kashiwabara, K., Tsurutani, J., Kitada, M., Takahashi, M., Kato, H., Kikawa, Y., Sakata, E., Naito, Y., Hasegawa, Y., Saito, T., Iwasa, T., Takashima, T., Aihara, T., Mukai, H., & Hara, F. (2022). Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. Breast cancer (Tokyo, Japan), 29(1), 186-188. https://doi.org/10.1007/s12282-021-01296-z
Taira, Naruto, et al. "Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer." Breast cancer (Tokyo, Japan) vol. 29,1 (2022): 186-188. doi: https://doi.org/10.1007/s12282-021-01296-z
Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Takashima T, Aihara T, Mukai H, Hara F. Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. Breast Cancer. 2022 Jan;29(1):186-188. doi: 10.1007/s12282-021-01296-z. PMID: 34562260.
Copy
Download .nbib